Guard Therapeutics
29 SEK 0%Vær den første som følger denne virksomhed
Guard Therapeutics is a developer of pharmaceuticals in the field of oxidative stress. The company focuses primarily on the research, development, and commercialization of pharmaceuticals that are intended to prevent the occurrence and complications of acute kidney damage. In preclinical studies, pharmaceuticals have been shown to protect exposed tissue and support regenerative processes. Treatment of acute kidney injuries in conjunction with heart surgery is a priority in clinical development.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
GUARD
Daglig lav / høj pris
28,6 / 29,6
SEK
Markedsværdi
349,62 mio. SEK
Aktieomsætning
47,75 t SEK
Volumen
1,6 t
Seneste videoer
Finanskalender
Delårsrapport
22.08.2024
Delårsrapport
13.11.2024
Årsrapport
20.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Jan Ståhlberg | 16,4 % | 16,4 % |
M2 Asset Management AB | 11,0 % | 11,0 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Guard Therapeutics research published in American Journal of Physiology – Renal Physiology
Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Guard Therapeutics presented development strategy and new preclinical results at R&D Update
Invitation to Guard Therapeutics’ R&D Update on January 30
FDA provides positive feedback to Guard Therapeutics regarding the continued development plan for RMC-035
Guard Therapeutics presents the Nomination Committee for 2024
Guard Therapeutics presents late breaking clinical trial abstract at ASN Kidney Week 2023
Guard Therapeutics provides more information on the development strategy for RMC-035
![Guard Therapeutics presents top-line results of Phase 2 (AKITA) study, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/114c4f69-b076-45ff-9309-99ce810fa536.png)